Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.58 |
| ▸ | PGR | P06401 | 3/20 | 0.58 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 14/20 | 0.56 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13809834 | 1.00 | AR (0.58) | ARPGRNR3C2CYP19A1SRD5A2 | |
| SCHEMBL7698849 | 0.81 | CYP19A1 (0.52) | CYP19A1 | |
| SCHEMBL13217275 | 0.81 | AR (0.57) | ARPGRNR3C2CYP19A1 | |
| SCHEMBL2929841 | 0.81 | AR (0.57) | ARPGRNR3C2CYP19A1 | |
| SCHEMBL8402139 | 0.81 | CYP19A1 (0.51) | CYP19A1 | |
| SCHEMBL12638972 | 0.80 | AR (0.56) | ARPGRNR3C2CYP19A1 | |
| SCHEMBL11809654 | 0.80 | PGR (0.64) | ARPGRNR3C2CYP19A1 | |
| SCHEMBL2832958 | 0.79 | SHBG (0.59) | ARPGRNR3C2CYP19A1SRD5A2 | |
| SCHEMBL8402137 | 0.79 | CYP19A1 (0.50) | CYP19A1 | |
| SCHEMBL7698847 | 0.79 | CYP19A1 (0.50) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560984-B1 | PROCESS FOR THE PREPARATION OF DIENOGEST SUBSTANTIALLY FREE OF IMPURITIES | LUPIN LTD (IN) | 2015-04-01 | — | — | EP | disclosed |
| EP-2560984-A2 | PROCESS FOR THE PREPARATION OF DIENOGEST SUBSTANTIALLY FREE OF IMPURITIES | Lupin Limited (IN) | 2013-02-27 | — | — | EP | disclosed |
| US-20130041166-A1 | PROCESS FOR THE PREPARATION OF DIENOGEST SUBSTANTIALLY FREE OF IMPURITIES | LUPIN LIMITED (IN) | 2013-02-14 | — | — | US | disclosed |
| WO-2011132045-A2 | PROCESS FOR THE PREPARATION OF DIENOGEST SUBSTANTIALLY FREE OF IMPURITIES | LUPIN LIMITED (IN) | 2011-10-27 | — | — | WO | disclosed |
| EP-2305694-A2 | Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | SRI International (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-2070941-A1 | Stereoselective synthesis of selective estrogen receptor down-regulators | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-06-17 | — | — | EP | disclosed |
| EP-1847548-A2 | Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | Sri International (US) | 2007-10-24 | — | — | EP | disclosed |
| EP-1226155-B1 | 18-NOR-STEROIDS AS SELECTIVELY ACTIVE ESTROGENS | BAYER SCHERING PHARMA AG (DE) | 2007-05-02 | — | — | EP | disclosed |
| US-20060079702-A1 | Process for making estra-4,9(10)-diene steroids | VAN RHEENEN VERLAN H | 2006-04-13 | — | — | US | disclosed |
| US-20050282791-A1 | 18-nor steroids as selectively active estrogens | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-12-22 | — | — | US | disclosed |
| US-5986115-A | STEROIDS WITH FLUORO GROUPS AND ETHER OR ESTER GROUPS | SCHERING AG (DE) | 1999-11-16 | — | — | US | disclosed |
| WO-1999046279-A2 | INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE | ENDORECHERCHE, INC. (CA) | 1999-09-16 | — | — | WO | disclosed |
| WO-1999033859-A2 | NOVEL ANTI-ESTROGENIC STEROIDS, AND ASSOCIATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | SRI INTERNATIONAL (US) | 1999-07-08 | — | — | WO | disclosed |
| EP-0920441-A1 | 7ALPHA-(EPSILON-AMINOALKYL)-ESTRATRIENES, PROCESS FOR PREPARING THE SAME, PHARMACEUTICAL PREPARATIONS CONTAINING SAID 7ALPHA-(EPSILON-AMINOALKYL)-ESTRATRIENES AND THEIR USE FOR PREPARING MEDICAMENT | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-06-09 | — | — | EP | disclosed |
| EP-0906332-A1 | 7$g(a)-(5-METHYLAMINOPENTYL)-ESTRATRIENES, PROCESS FOR THE PREPARATION THEREOF, PHARMACEUTICAL PREPARATIONS WHICH CONTAIN SAID 7$g(a)-(5-METHYLAMINOPENTYL)-ESTRATRIENES AND USE THEREOF FOR PRODUCTION OF DRUGS | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-04-07 | — | — | EP | disclosed |
| US-5866560-A | ESTROGEN INHIBITORS; TUMOR THERAPY; HORMONE REPLACEMENT THERAPY | SCHERING AG (DE) | 1999-02-02 | — | — | US | disclosed |
| WO-1998007740-A1 | 7α-(κ-AMINOALKYL)ESTRATRIENES, PROCESS FOR PREPARING THE SAME, PHARMACEUTICAL PREPARATIONS CONTAINING SAID 7α-(κ-AMINOALKYL)ESTRATRIENES AND THEIR USE FOR PREPARING MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-02-26 | — | — | WO | disclosed |
| WO-1997045441-A1 | 7α-(5-METHYLAMINOPENTYL)-ESTRATRIENES, PROCESS FOR THE PREPARATION THEREOF, PHARMACEUTICAL PREPARATIONS WHICH CONTAIN SAID 7α-(5-METHYLAMINOPENTYL)-ESTRATRIENES AND USE THEREOF FOR PRODUCTION OF DRUGS | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-12-04 | — | — | WO | disclosed |
| EP-0410554-A2 | 14,17-Alpha-ethano- and ethano-estratrienes, process for their production and their use in the production of pharmaceuticals | SCHERING AKTIENGESELLSCHAFT (DE) | 1991-01-30 | — | — | EP | disclosed |
| US-4073899-A | 7A-METHYL-ESTR-5-ENE-3B,17B-DIOL AND 17-ACYL ESTERS | RICHARDSON-MERRELL, INC. (US) | 1978-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130041166-A1 | PROCESS FOR THE PREPARATION OF DIENOGEST SUBSTANTIALLY FREE OF IMPURITIES | CYP19A1, CYP17A1, HSD17B11 | AR 100/4885PGR 24/4885NR3C2 42/4885 |
| US-20060079702-A1 | Process for making estra-4,9(10)-diene steroids | CYP19A1, NR5A1, HSD17B11 | AR 29/4885PGR 31/4885NR3C2 12/4885 |
| US-20050282791-A1 | 18-nor steroids as selectively active estrogens | GPER1, ESR2, ESRRA | AR 13/4885PGR 15/4885NR3C2 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.